• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在印度尼西亚出现新型严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变种的情况下评估2019冠状病毒病(COVID-19)病例的潜在激增及加强疫苗的需求:来自西爪哇的一项建模研究

Assessing potential surge of COVID-19 cases and the need for booster vaccine amid emerging SARS-CoV-2 variants in Indonesia: A modelling study from West Java.

作者信息

Nuraini Nuning, Soekotjo Fadiya Nadhilah, Alifia Almira, Sukandar Kamal Khairudin, Lestari Bony Wiem

机构信息

Department of Mathematics, Institut Teknologi Bandung, Bandung, 40132, Indonesia.

Research Center for Care and Control of Infectious Disease, Universitas Padjadjaran, Bandung, 40161, Indonesia.

出版信息

Heliyon. 2023 Sep 9;9(9):e20009. doi: 10.1016/j.heliyon.2023.e20009. eCollection 2023 Sep.

DOI:10.1016/j.heliyon.2023.e20009
PMID:37809646
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10559733/
Abstract

OBJECTIVES

Primary and booster vaccinations are crucial in COVID-19 control. This study aimed to assess the minimum booster coverage to hamper potential surge of COVID-19 cases in 2023 in Indonesia, a low-resource setting country.

METHODS

We used a modified SEIR compartment model to assess different scenarios in booster coverage across West Java population: 35%, 50%, and 70%. We fitted the model, then we calculated the potential active cases in 2023 if each scenario was met before 2022 ends. A heat map of predicted cases from various booster coverages and time frames was produced and matched with vaccination rate's function to determine feasible time frames.

RESULTS

A minimum of 70% booster coverage in West Java is needed to reduce 90% of potential COVID-19 cases and avert possible surge in 2023. The booster doses should be distributed before February 2023 to achieve its optimum preventive effect. Delays in achieving minimum booster coverage is acceptable, but higher booster coverage will be required.

CONCLUSIONS

For better COVID-19 control in Indonesia, booster vaccination is warranted, as presented by a case study in West Java. Sufficient vaccine supplies, infrastructure, and healthcare workers should be ensured to support a successful booster vaccination program.

摘要

目的

新冠疫苗的初次接种和加强接种对于控制新冠疫情至关重要。本研究旨在评估在资源匮乏的印度尼西亚,为遏制2023年新冠病例可能出现的激增情况所需的最低加强针接种覆盖率。

方法

我们使用了一个经过修改的SEIR compartment模型来评估西爪哇省不同加强针接种覆盖率的情景:35%、50%和70%。我们对模型进行了拟合,然后计算了如果在2022年底前实现每种情景,2023年可能出现的活跃病例数。绘制了不同加强针接种覆盖率和时间框架下预测病例的热图,并将其与接种率函数相匹配,以确定可行的时间框架。

结果

西爪哇省至少需要70%的加强针接种覆盖率,才能减少90%的潜在新冠病例,并避免2023年可能出现的激增。加强针应在2023年2月前分发,以达到最佳预防效果。推迟实现最低加强针接种覆盖率是可以接受的,但需要更高的加强针接种覆盖率。

结论

正如西爪哇省的案例研究所示,为了在印度尼西亚更好地控制新冠疫情,加强针接种是必要的。应确保有足够的疫苗供应、基础设施和医护人员,以支持成功的加强针接种计划。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f40/10559733/53fb083fd14c/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f40/10559733/b7a4b3d43c80/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f40/10559733/9f1c176675f0/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f40/10559733/53fb083fd14c/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f40/10559733/b7a4b3d43c80/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f40/10559733/9f1c176675f0/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3f40/10559733/53fb083fd14c/gr3.jpg

相似文献

1
Assessing potential surge of COVID-19 cases and the need for booster vaccine amid emerging SARS-CoV-2 variants in Indonesia: A modelling study from West Java.在印度尼西亚出现新型严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变种的情况下评估2019冠状病毒病(COVID-19)病例的潜在激增及加强疫苗的需求:来自西爪哇的一项建模研究
Heliyon. 2023 Sep 9;9(9):e20009. doi: 10.1016/j.heliyon.2023.e20009. eCollection 2023 Sep.
2
Persistence and Protective Potential of SARS-CoV-2 Antibody Levels After COVID-19 Vaccination in a West Virginia Nursing Home Cohort.西弗吉尼亚州养老院队列中 COVID-19 疫苗接种后 SARS-CoV-2 抗体水平的持久性和保护潜力。
JAMA Netw Open. 2022 Sep 1;5(9):e2231334. doi: 10.1001/jamanetworkopen.2022.31334.
3
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.COVID-19 疫苗效力下降和加强针的有效性和副作用:来自 ZOE COVID 研究的一项前瞻性社区研究。
Lancet Infect Dis. 2022 Jul;22(7):1002-1010. doi: 10.1016/S1473-3099(22)00146-3. Epub 2022 Apr 8.
4
Assessing the potential impact of COVID-19 booster doses and oral antivirals: A mathematical modelling study of selected middle-income countries in the Indo-Pacific.评估新冠病毒加强针和口服抗病毒药物的潜在影响:对印度-太平洋地区部分中等收入国家的数学建模研究
Vaccine X. 2023 Sep 9;15:100386. doi: 10.1016/j.jvacx.2023.100386. eCollection 2023 Dec.
5
Efficacy and Safety of a Booster Vaccination with Two Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: Results of a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial in Abu Dhabi.两种灭活严重急性呼吸综合征冠状病毒2疫苗加强接种对成人有症状的冠状病毒病感染的疗效和安全性:在阿布扎比进行的一项双盲、随机、安慰剂对照3期试验的结果
Vaccines (Basel). 2023 Jan 30;11(2):299. doi: 10.3390/vaccines11020299.
6
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.同源加强接种 SARS-CoV-2 重组刺突蛋白疫苗(NVX-CoV2373)的安全性和免疫原性:一项随机、安慰剂对照、2 期临床试验的二次分析。
Lancet Infect Dis. 2022 Nov;22(11):1565-1576. doi: 10.1016/S1473-3099(22)00420-0. Epub 2022 Aug 10.
7
[COVID-19 infections and effectiveness of the vaccination among healthcare workers].[医护人员中的新冠病毒感染情况及疫苗接种效果]
Orv Hetil. 2023 Feb 5;164(5):163-171. doi: 10.1556/650.2023.32709.
8
Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.在接种一剂灭活全病毒 COVID-19 疫苗(VLA2001)加强针后针对原始株、Delta 株和奥密克戎株变异病毒的安全性和免疫原性:COV-COMPARE 随机对照 3 期试验开放标签扩展的中期分析。
J Infect. 2023 Sep;87(3):242-254. doi: 10.1016/j.jinf.2023.06.022. Epub 2023 Jul 3.
9
Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant - United States, February 14-March 27, 2022.奥密克戎变异株广泛传播期间,养老院居民接种 COVID-19 追加初级或加强疫苗剂量对预防 SARS-CoV-2 感染的效果-美国,2022 年 2 月 14 日-3 月 27 日。
MMWR Morb Mortal Wkly Rep. 2022 May 6;71(18):633-637. doi: 10.15585/mmwr.mm7118a4.
10
Acceptance of the COVID-19 vaccine booster dose and associated factors among the elderly in China based on the health belief model (HBM): A national cross-sectional study.基于健康信念模型(HBM)的中国老年人对 COVID-19 疫苗加强针的接受情况及其影响因素:一项全国性横断面研究。
Front Public Health. 2022 Dec 15;10:986916. doi: 10.3389/fpubh.2022.986916. eCollection 2022.

引用本文的文献

1
Tracking the financial flows of Indonesia's COVID-19 vaccination program.追踪印度尼西亚新冠疫苗接种计划的资金流向。
PLOS Glob Public Health. 2025 Aug 5;5(8):e0005041. doi: 10.1371/journal.pgph.0005041. eCollection 2025.

本文引用的文献

1
New compartment model for COVID-19.COVID-19 的新型隔室模型。
Sci Rep. 2023 Apr 3;13(1):5409. doi: 10.1038/s41598-023-32159-6.
2
Numerical solution of COVID-19 pandemic model via finite difference and meshless techniques.基于有限差分法和无网格法的新冠肺炎疫情模型数值解
Eng Anal Bound Elem. 2023 Feb;147:76-89. doi: 10.1016/j.enganabound.2022.11.026. Epub 2022 Nov 28.
3
A COVID-19 model incorporating variants, vaccination, waning immunity, and population behavior.纳入变异株、疫苗接种、免疫衰减和人群行为的 COVID-19 模型。
Sci Rep. 2022 Nov 27;12(1):20377. doi: 10.1038/s41598-022-24967-z.
4
A model of COVID-19 pandemic with vaccines and mutant viruses.一种带有疫苗和变异病毒的 COVID-19 大流行模型。
PLoS One. 2022 Oct 24;17(10):e0275851. doi: 10.1371/journal.pone.0275851. eCollection 2022.
5
Effectiveness of Messenger RNA-1273 Vaccine Booster Against Coronavirus Disease 2019 in Immunocompetent Adults.mRNA-1273 疫苗加强针在免疫功能正常成年人中预防 2019 冠状病毒病的效果。
Clin Infect Dis. 2023 Jan 13;76(2):252-262. doi: 10.1093/cid/ciac785.
6
Effectiveness of COVID-19 vaccine booster in the general population and in subjects with comorbidities. A population-based study in Spain.新冠疫苗加强针在普通人群和合并症患者中的效果。西班牙的一项基于人群的研究。
Environ Res. 2022 Dec;215(Pt 2):114252. doi: 10.1016/j.envres.2022.114252. Epub 2022 Sep 10.
7
COVID-19 Vaccine Booster Strategies in Light of Emerging Viral Variants: Frequency, Timing, and Target Groups.鉴于新出现的病毒变种的新冠疫苗加强针策略:频率、时机和目标群体
Infect Dis Ther. 2022 Oct;11(5):2045-2061. doi: 10.1007/s40121-022-00683-z. Epub 2022 Sep 12.
8
Analysis of COVID-19 in India using a vaccine epidemic model incorporating vaccine effectiveness and herd immunity.使用纳入疫苗效力和群体免疫的疫苗流行模型对印度的新冠疫情进行分析。
Eur Phys J Plus. 2022;137(9):1003. doi: 10.1140/epjp/s13360-022-03216-2. Epub 2022 Sep 5.
9
Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis.异源加强免疫与同源加强免疫对 SARS-CoV-2 疫苗有效性和安全性的比较:系统评价和荟萃分析。
Int J Environ Res Public Health. 2022 Aug 29;19(17):10752. doi: 10.3390/ijerph191710752.
10
Usage of Compartmental Models in Predicting COVID-19 Outbreaks.房室模型在预测 COVID-19 爆发中的应用。
AAPS J. 2022 Sep 2;24(5):98. doi: 10.1208/s12248-022-00743-9.